Ascentage Pharma (ADR) (AAPG)
Develops and commercializes hematology therapies in China and global clinical trials.
Something off on this page? Send us feedback.
Develops and commercializes small-molecule therapies for hematologic malignancies. China-approved olverembatinib and lisaftoclax form its commercial base, while global Phase III programs seek additional uses; no named product or pipeline program is approved by the U.S. FDA.
Discovers, develops and commercializes small-molecule therapies for hematologic malignancies. Its drug-discovery work targets apoptosis pathways and kinase mutations; China-approved olverembatinib treats CML, while lisaftoclax is approved for specified previously treated adult CLL/SLL patients.
Commercial activity is centered in China, alongside global Phase III programs investigating expanded uses for both products across CML, Ph+ ALL, CLL/SLL, AML, higher-risk MDS and SDH-deficient GIST. The platforms encompass Bcl-2, MDM2-p53 and kinase-mutation targets.
Chinese approvals underpin the commercial base, while the named products and pipeline programs have not been approved by the U.S. FDA.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $283.0M · Total debt $312.7M · Total assets $483.8M · Shareholders' equity $83.1M
- Revenue
- $44.6M
- Operating income
- −$111.0M
- Net income
- −$120.5M
Reported in CNY, converted at the latest exchange rate
No dividends on record.
| Institutions | 0.06% | 15.0K ADS | |
|---|---|---|---|
| 7 holders · as of Jun 30, 2026 | |||
| Other | 99.94% | 23.23M ADS | |
| remainder | |||
23.24M ADS as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Point72 Asset Management, L.P.Institution | 0.06% | 13,841 ADS | as of Jun 30, 2026 |
Morgan StanleyInstitution | 0.00% | 919 ADS | as of Jun 30, 2026 |
Wells Fargo & Company/MNInstitution | 0.00% | 200 ADS | as of Jun 30, 2026 |
Eversource Wealth Advisors, LLCInstitution | 0.00% | 24 ADS | as of Jun 30, 2026 |
UBS Group AGInstitution | 0.00% | 15 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- AbbVie
VENCLEXTA is an established BCL-2 option in CLL/SLL
- Novartis (ADR)
Scemblix overlaps in T315I and previously treated CML
- Takeda (ADR)
ICLUSIG overlaps in resistant and T315I-positive CML
- BeOne Medicines (ADR)
Sonrotoclax is a BCL-2 rival in post-BTKi CLL/SLL
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Ascentage Pharma (ADR) | $15.51 | −2.27% | $1.48B | — | — | 15.6 | +35.3% |
| AbbVie | $264.77 | −0.16% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Novartis (ADR) | $142.25 | +0.68% | $268.53B | 21.3 | 15.1 | 4.8 | +0.9% |
| Takeda (ADR) | $18.85 | −0.55% | $60.30B | 52.9 | 60.0 | 2.0 | +4.2% |
| BeOne Medicines (ADR) | $362.88 | −1.41% | $39.33B | 5.1 | 46.0 | 6.4 | +29.6% |
| Median | 37.1 | 31.7 | 5.6 | +7.2% |